Amphastar 制药

Amphastar Pharmaceuticals Inc may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 28% discount to our quantitative fair value estimate of $35.26 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 71.0% sits in the top 45% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 11.8%, for example, sits in the top 20% globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.